Vascular Biogenics Ltd (VBLT)

[davidal66]

The limited disease cohort with VB-111 as mono therapy, then, upon progression, VB-111 was stopped and patients returned to standard of care... nothing, avastin, steroids, who knows and had a median overall survival of a little over eight months, similar to what's expected with Avastin only.

The so-called continuous cohort, began as VB-111 as mono therapy, then, upon progression after FDA amendment, combination therapy with VB-111 with Avastin and had a median overall survival of over 14 months.

The best distillation of this can be found on the archived events on the companies website under the SNO presentation from late '15. There are also waterfall plots with best tumor size responses on this as well.